Historical Valuation
Neuropace Inc (NPCE) is now in the Fair zone, suggesting that its current forward PS ratio of 5.23 is considered Fairly compared with the five-year average of -9.02. The fair price of Neuropace Inc (NPCE) is between 9.18 to 22.63 according to relative valuation methord.
Relative Value
Fair Zone
9.18-22.63
Current Price：16.69
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Neuropace Inc (NPCE) has a current Price-to-Book (P/B) ratio of 27.26. Compared to its 3-year average P/B ratio of 18.41 , the current P/B ratio is approximately 48.05% higher. Relative to its 5-year average P/B ratio of 12.59, the current P/B ratio is about 116.54% higher. Neuropace Inc (NPCE) has a Forward Free Cash Flow (FCF) yield of approximately -3.28%. Compared to its 3-year average FCF yield of -12.32%, the current FCF yield is approximately -73.36% lower. Relative to its 5-year average FCF yield of -16.52% , the current FCF yield is about -80.13% lower.
P/B
Median3y
18.41
Median5y
12.59
FCF Yield
Median3y
-12.32
Median5y
-16.52
Competitors Valuation Multiple
AI Analysis for NPCE
The average P/S ratio for NPCE competitors is 7.33, providing a benchmark for relative valuation. Neuropace Inc Corp (NPCE.O) exhibits a P/S ratio of 5.23, which is -28.55% above the industry average. Given its robust revenue growth of 29.89%, this premium appears sustainable.
Performance Decomposition
AI Analysis for NPCE
1Y
3Y
5Y
Market capitalization of NPCE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NPCE in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NPCE currently overvalued or undervalued?
Neuropace Inc (NPCE) is now in the Fair zone, suggesting that its current forward PS ratio of 5.23 is considered Fairly compared with the five-year average of -9.02. The fair price of Neuropace Inc (NPCE) is between 9.18 to 22.63 according to relative valuation methord.
What is Neuropace Inc (NPCE) fair value?
NPCE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Neuropace Inc (NPCE) is between 9.18 to 22.63 according to relative valuation methord.
How does NPCE's valuation metrics compare to the industry average?
The average P/S ratio for NPCE's competitors is 7.33, providing a benchmark for relative valuation. Neuropace Inc Corp (NPCE) exhibits a P/S ratio of 5.23, which is -28.55% above the industry average. Given its robust revenue growth of 29.89%, this premium appears sustainable.
What is the current P/B ratio for Neuropace Inc (NPCE) as of Jan 10 2026?
As of Jan 10 2026, Neuropace Inc (NPCE) has a P/B ratio of 27.26. This indicates that the market values NPCE at 27.26 times its book value.
What is the current FCF Yield for Neuropace Inc (NPCE) as of Jan 10 2026?
As of Jan 10 2026, Neuropace Inc (NPCE) has a FCF Yield of -3.28%. This means that for every dollar of Neuropace Inc’s market capitalization, the company generates -3.28 cents in free cash flow.
What is the current Forward P/E ratio for Neuropace Inc (NPCE) as of Jan 10 2026?
As of Jan 10 2026, Neuropace Inc (NPCE) has a Forward P/E ratio of -22.27. This means the market is willing to pay $-22.27 for every dollar of Neuropace Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Neuropace Inc (NPCE) as of Jan 10 2026?
As of Jan 10 2026, Neuropace Inc (NPCE) has a Forward P/S ratio of 5.23. This means the market is valuing NPCE at $5.23 for every dollar of expected revenue over the next 12 months.